Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
Earnings Data
Report Date
Nov 10, 2025TBA (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.23Last Year’s EPS
-0.23Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive sentiment, driven by progress in clinical trials and strategic partnerships, despite financial and legal challenges. The successful advancement of pivotal trials and the strong collaboration with AstraZeneca are significant positives. However, the arbitration with Servier presents a notable uncertainty.Company Guidance
Pivotal Phase II Trial Initiation
Cellectis is preparing to initiate a pivotal Phase II trial for lasme-cel, UCART22, in relapsed or refractory acute lymphoblastic leukemia in the second half of 2025, following successful end of Phase I discussions with the FDA and EMA.
Strategic Collaboration with AstraZeneca
Research and development activities are ongoing under the partnership with AstraZeneca, covering three cell and gene therapy programs targeting hematological malignancies, solid tumors, and a genetic disorder.
Financial Sufficiency
Cellectis reports a cash position of $230 million as of June 30, 2025, sufficient to fund operations into H2 2027, including pivotal studies for lasme-cel and eti-cel.
Expansion of Clinical Trial Sites
Cellectis is expanding clinical trial sites in the United States and Europe, including the UK, to accelerate recruitment for the Phase II study of UCART22.
CLLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CLLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 04, 2025 | $3.02 | $2.53 | -16.23% |
May 12, 2025 | $1.51 | $1.41 | -6.62% |
Mar 13, 2025 | $1.29 | $1.24 | -3.88% |
Nov 04, 2024 | $1.76 | $1.78 | +1.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Cellectis SA (CLLS) report earnings?
Cellectis SA (CLLS) is schdueled to report earning on Nov 10, 2025, TBA (Confirmed).
What is Cellectis SA (CLLS) earnings time?
Cellectis SA (CLLS) earnings time is at Nov 10, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CLLS EPS forecast?
CLLS EPS forecast for the fiscal quarter 2025 (Q3) is -0.23.